Preprint Article Version 1 NOT YET PEER-REVIEWED

Strategies in the Design of Antidiabetic Drugs from Terminalia Chebula Retz. Using in silico and in vitro Approach

  1. Pravara Institute of Medical Sciences (DU), Loni (Bk), Tal. Rahata, Dist.Ahmednagar, (MS) India-413736
  2. Arts, Science & Commerce College, Rahata, Tal-Rahata, Dist. Ahmednagar (MS) India –423 107
Version 1 : Received: 15 September 2016 / Approved: 20 September 2016 / Online: 20 September 2016 (16:13:12 CEST)

How to cite: Bansode, T.; Salalkar, B. Strategies in the Design of Antidiabetic Drugs from Terminalia Chebula Retz. Using in silico and in vitro Approach. Preprints 2016, 2016090073 (doi: 10.20944/preprints201609.0073.v1). Bansode, T.; Salalkar, B. Strategies in the Design of Antidiabetic Drugs from Terminalia Chebula Retz. Using in silico and in vitro Approach. Preprints 2016, 2016090073 (doi: 10.20944/preprints201609.0073.v1).

Abstract

Diabetes mellitus is the fifth deadliest disease in the developing countries. Even with all the research and new drugs available, combating diabetes is still challenging. There are successes in finding new cost effective drugs without side effects, even if not perfect. In our investigation we studied binding mechanism of secondary metabolite of T. chebula in silico. It was observed that three compounds out of 16 have a higher binding affinity for the target proteins. Ellagic acid showed highest binding affinity with alpha amylase, beta glucosidase and alpha glucosidase with lesser binding energies -4.5kcal/mol, -5.36kcal/mol and -4.48kcal/mol respectively. Arjungenin has lesser binding energy of 4.77 kcal/mol with glucokinase while luteoline has binding energy of -7.25kcal/mol for enzyme glycogen synthase kinase. These entire compounds interacted with non-covalent interaction. Petroleum ether extract showed the significant alpha amylase inhibitory activity i.e. 51.22% as compared to standard drug (65.99%).TLC analysis revealed the presence of total 9 compounds in different plant extracts one of them might be a lead compound which could be further exploited for the development of novel safer and potent antidiabetic drug.

Subject Areas

diabetes mellitus, molecular docking, thin layer chromatography, alpha amylase, ellagic acid

Readers' Comments and Ratings (0)

Discuss and rate this article
Views 99
Downloads 145
Comments 0
Metrics 0
Discuss and rate this article

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.